RAPT Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . RAPT Therapeutics
RAPT Stock  USD 1.09  0.03  2.68%   
RAPT Therapeutics financial statements provide useful quarterly and yearly information to potential RAPT Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on RAPT Therapeutics financial statements helps investors assess RAPT Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting RAPT Therapeutics' valuation are summarized below:
Gross Profit
1.5 M
Market Capitalization
147.8 M
Enterprise Value Revenue
677.3673
Earnings Share
(3.19)
Quarterly Revenue Growth
(1.00)
There are currently one hundred twenty trending fundamental ratios for RAPT Therapeutics that can be evaluated and compared over time across competitors. All traders should check out RAPT Therapeutics' recent fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 70.4 M in 2025. Enterprise Value is likely to gain to about (110.2 M) in 2025

RAPT Therapeutics Total Revenue

1.53 Million

Check RAPT Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among RAPT Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 952.3 K, Interest Expense of 1.3 M or Selling General Administrative of 16.7 M, as well as many indicators such as Price To Sales Ratio of 208, Dividend Yield of 0.0 or PTB Ratio of 0.32. RAPT financial statements analysis is a perfect complement when working with RAPT Therapeutics Valuation or Volatility modules.
  
Check out the analysis of RAPT Therapeutics Correlation against competitors.
For more information on how to buy RAPT Stock please use our How to Invest in RAPT Therapeutics guide.

RAPT Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets165.3 M240.3 M107.5 M
Slightly volatile
Other Current Liabilities46.9 M44.7 M9 M
Slightly volatile
Total Current Liabilities50.8 M48.4 M12.3 M
Slightly volatile
Other Liabilities2.2 M3.1 M1.7 M
Slightly volatile
Property Plant And Equipment Net5.1 M4.7 M3.5 M
Slightly volatile
Accounts Payable2.5 M1.3 M1.8 M
Slightly volatile
Cash178.2 M169.7 M62.8 M
Slightly volatile
Non Current Assets Total6.9 M5.1 M4.5 M
Slightly volatile
Non Currrent Assets Other369.6 K389 K915.2 K
Slightly volatile
Other Assets1.091.15625.8 K
Slightly volatile
Cash And Short Term Investments155.2 M231.1 M101 M
Slightly volatile
Common Stock Total Equity2.4 K3.5 K1.8 K
Slightly volatile
Common Stock Shares Outstanding29.8 M40.8 M21.7 M
Slightly volatile
Liabilities And Stockholders Equity165.3 M240.3 M107.5 M
Slightly volatile
Non Current Liabilities Total2 M2.1 M56.3 M
Slightly volatile
Capital Surpluse740.3 M705 M242.9 M
Slightly volatile
Other Current Assets4.2 M4.2 M2.5 M
Slightly volatile
Other Stockholder Equity439.5 M804.4 M237.8 M
Slightly volatile
Total Liabilities25.5 M50.4 M66.9 M
Slightly volatile
Property Plant And Equipment Gross7.8 M14.8 M4.9 M
Slightly volatile
Total Current Assets158.4 M235.2 M103 M
Slightly volatile
Net Working Capital141.5 M186.9 M92.9 M
Slightly volatile
Common Stock13.7 K13 K3.1 K
Slightly volatile
Property Plant Equipment2.4 M2.3 M2.4 M
Slightly volatile
Capital Stock13.7 K13 K3.6 K
Slightly volatile
Current Deferred Revenue868.7 K914.4 K3.1 M
Slightly volatile
Short Term Debt3.2 M2.4 M3.8 M
Very volatile
Short Term Investments101.6 M61.3 M100.2 M
Slightly volatile
Deferred Long Term Liabilities2.3 M2.4 M2.9 M
Slightly volatile
Short and Long Term Debt Total5.4 M4.5 M8.4 M
Slightly volatile
Non Current Liabilities Other5.5 M6.1 M6.7 M
Slightly volatile

RAPT Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization952.3 K1.1 M1.3 M
Slightly volatile
Selling General Administrative16.7 M28.9 M10.3 M
Slightly volatile
Other Operating Expenses153.4 M146.1 M60 M
Slightly volatile
Research Development64.6 M107.2 M44.6 M
Slightly volatile
Total Operating Expenses81.4 M136.1 M54.9 M
Slightly volatile
Reconciled Depreciation946.5 K1.2 M1.3 M
Slightly volatile
Total Other Income Expense Net6.5 M6.2 M1.9 M
Slightly volatile
Tax Provision170.1 K179.1 K533.5 K
Slightly volatile
Cost Of Revenue2.4 M4.1 M1.8 M
Slightly volatile
Non Operating Income Net Other1.2 M2.3 M1.4 M
Pretty Stable
Selling And Marketing Expenses2.8 M3.2 M3.5 M
Slightly volatile

RAPT Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock158.4 M150.9 M63 M
Slightly volatile
Stock Based Compensation20.9 M19.9 M6.1 M
Slightly volatile
Begin Period Cash Flow37 M47.5 M45.4 M
Pretty Stable
Other Cashflows From Financing Activities802.8 K845 K21.8 M
Slightly volatile
Depreciation953.6 K1.2 M1.3 M
Slightly volatile
Capital Expenditures115.9 K122 K1 M
Slightly volatile
Total Cash From Financing Activities87.3 M152.9 M58.3 M
Slightly volatile
End Period Cash Flow178.2 M169.7 M62.8 M
Slightly volatile
Change To Netincome14.4 M13.7 M5 M
Slightly volatile
Issuance Of Capital Stock105.8 M152 M75.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio208380171
Slightly volatile
Stock Based Compensation To Revenue6.976.643.1202
Slightly volatile
Capex To Depreciation0.09630.10140.8148
Pretty Stable
EV To Sales200362163
Slightly volatile
Payables Turnover0.950.791.0081
Slightly volatile
Sales General And Administrative To Revenue12.5311.935.1898
Slightly volatile
Research And Ddevelopement To Revenue41.5139.5417.6931
Slightly volatile
Capex To Revenue0.520.50.1996
Slightly volatile
Cash Per Share3.955.66854.1546
Slightly volatile
Days Payables Outstanding377479404
Slightly volatile
Income Quality0.910.64140.8789
Slightly volatile
Current Ratio4.624.865212.8843
Slightly volatile
Capex Per Share0.00280.0030.0606
Slightly volatile
Revenue Per Share0.05130.0540.1648
Slightly volatile
Interest Debt Per Share0.10.11024.4309
Slightly volatile
Debt To Assets0.01780.01871.2359
Slightly volatile
Days Of Payables Outstanding377479404
Slightly volatile
Ebt Per Ebit1.070.95420.9866
Very volatile
Long Term Debt To Capitalization0.01180.01241.1804
Slightly volatile
Total Debt To Capitalization0.0220.02311.234
Slightly volatile
Quick Ratio4.624.865212.8843
Slightly volatile
Net Income Per E B T1.11.121.0209
Slightly volatile
Cash Ratio6.843.51059.9392
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.00151.04
Very volatile
Fixed Asset Turnover0.180.191.2926
Slightly volatile
Debt Ratio0.01780.01871.2359
Slightly volatile
Price Sales Ratio208380171
Slightly volatile
Asset Turnover0.00630.00660.0319
Slightly volatile

RAPT Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap70.4 M74.1 M486.5 M
Slightly volatile

RAPT Fundamental Market Drivers

Cash And Short Term Investments231.1 M

RAPT Upcoming Events

12th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About RAPT Therapeutics Financial Statements

RAPT Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although RAPT Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in RAPT Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on RAPT Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue914.4 K868.7 K
Cost Of Revenue4.1 M2.4 M
Stock Based Compensation To Revenue 6.64  6.97 
Sales General And Administrative To Revenue 11.93  12.53 
Research And Ddevelopement To Revenue 39.54  41.51 
Capex To Revenue 0.50  0.52 
Revenue Per Share 0.05  0.05 
Ebit Per Revenue(64.61)(61.38)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY